FDA Support for Conferences and Scientific Meetings (R13 Clinical Trial Not Allowed)
ID: 344880Type: Posted
Overview

Buyer

Food and Drug Administration (HHS-FDA)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/344880

Additional Information

https://grants.nih.gov/grants/guide/pa-files/PAR-23-072.html
Timeline
    Description

    The Food and Drug Administration (FDA) is offering a grant opportunity titled "FDA Support for Conferences and Scientific Meetings (R13 Clinical Trial Not Allowed)" aimed at facilitating high-quality conferences and scientific meetings that align with the FDA's public health mission. The program seeks to provide federal financial assistance for events such as symposia, workshops, and seminars, which are essential for exchanging information on topics impacting public health. With an estimated total program funding of $1,000,000 and an expected 20 awards, applicants must submit a Letter of Intent at least eight weeks prior to the application deadlines, which occur in April and October each year until 2025. For further inquiries, interested parties can contact Janelle Fundersburg at janelle.fundersburg@fda.hhs.gov or by phone at 301-798-2533.

    Files
    Title
    Posted
    PAR-23-072_ FDA Support for Conferences...pdf
    PAR-23-072_.pdf
    The file pertains to the process of issuing Requests for Proposals (RFPs) and federal grants at local and state levels, which are essential mechanisms for government entities to procure services or funding for various projects. It outlines the regulations, criteria, and procedures involved in creating and submitting RFPs to ensure transparency and fairness in the selection process. Furthermore, the document emphasizes the importance of compliance with both federal and state laws while managing funds and executing awarded contracts. It discusses key aspects such as eligibility, evaluation criteria, proposal submission guidelines, and reporting obligations for grant recipients. The primary goal of these RFPs and grants is to promote accountability, achieve strategic objectives, and drive community development through effective collaboration with private and non-profit sectors. Overall, the document serves as a foundational guide for stakeholders engaged in government funding processes, ensuring that projects align with public interest and regulatory requirements.
    PAR-23-072.html
    The U.S. Food and Drug Administration (FDA) has announced a Funding Opportunity Announcement (FOA) to support high-quality conferences and scientific meetings through the R13 Clinical Trial Not Allowed grant mechanism. This program aims to align with the FDA's public health mission by financially assisting events such as symposia and workshops. Applicants must secure advance permission to submit grant applications by sending a Letter of Intent at least eight weeks before the application due dates, scheduled for April and October each year until 2025. Funding levels vary by FDA components, with specific caps on total costs for different centers, including up to $250,000 for the Center for Biologics Evaluation and Research (CBER) and unlimited for the Center for Devices and Radiological Health (CDRH). The FOA emphasizes diversity and inclusion in conference planning and requires a detailed diversity plan to enhance participation from underrepresented groups. Applicants are advised to submit applications early to allow for error corrections before the deadline, as late submissions will not be accepted. The document outlines detailed eligibility requirements, application procedures, and review criteria that emphasize scientific merit, innovation, and appropriateness of the conference objectives.
    Similar Opportunities
    Collaborations to Enhance Drug Development and Regulatory Science
    Food and Drug Administration
    The Food and Drug Administration (FDA) is inviting applications for a federal grant titled "Collaborations to Enhance Drug Development and Regulatory Science." This opportunity aims to establish cooperative agreements that support Public-Private Partnerships and collaborative activities under the Critical Path Initiative, focusing on innovative projects that enhance drug product development, advanced manufacturing, and the translation of scientific discoveries into therapeutics. The initiative is crucial for fostering innovation in drug safety, efficacy, quality, and performance, with a total funding ceiling of $5 million available for six expected awards in fiscal year 2024. Interested applicants can reach out to Terrin Brown at terrin.brown@fda.hhs.gov or call (240) 402-7610 for further information.
    Clinical Studies of Orphan Products Addressing Unmet Needs of Rare Diseases (R01 Clinical Trials Required)
    Food and Drug Administration
    The Food and Drug Administration (FDA) is offering a federal grant opportunity titled "Clinical Studies of Orphan Products Addressing Unmet Needs of Rare Diseases (R01 Clinical Trials Required)." This grant aims to fund clinical trials that evaluate the efficacy and safety of products intended to address unmet needs in rare diseases or conditions, with the goal of increasing the number of approved treatments in this area. The initiative is crucial for enhancing drug development for rare diseases, thereby potentially improving patient outcomes. Interested applicants, including higher education institutions, nonprofits, for-profit organizations, and various levels of government, can reach out to Kimberly Pendleton at Kimberly.Pendleton@fda.hhs.gov or call 240-402-7610 for more information. The opportunity is currently posted for the fiscal year 2025, with no cost-sharing or matching requirements.
    NIH Support for Conferences and Scientific Meetings (Parent R13 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity through the NIH Research Conference Grant (R13) to support high-quality scientific conferences that align with public health and the scientific missions of participating Institutes and Centers. This initiative encourages diverse participation and requires applicants to submit a detailed diversity plan, conference objectives, and logistical arrangements, while ensuring that costs align with actual project needs. The funding is crucial for fostering inclusive environments at scientific gatherings, with applications evaluated based on significance, innovation, approach, and diversity. Interested applicants can find more information and guidelines at the NIH website, with the application submission period opening on March 12, 2024, and closing on January 8, 2027. For inquiries, contact NIH Grants Information at grantsinfo@nih.gov.
    Laboratory Flexible Funding Model (LFFM)
    Food and Drug Administration
    The Food and Drug Administration (FDA) is offering a funding opportunity titled the Laboratory Flexible Funding Model (LFFM) aimed at enhancing the capacities of state human and animal food testing laboratories to support an integrated food safety system. This cooperative agreement focuses on prioritized sample testing and method development in microbiology, chemistry, and radiochemistry, with the goal of improving food safety and defense capabilities. The program is crucial for preventing foodborne illnesses and ensuring the safety of food in the U.S., with approximately $25 million in funding anticipated for fiscal year 2025 and a total of 75 awards expected. Eligible applicants include accredited private institutions of higher education and government entities, with key deadlines starting with letters of intent due on January 17, 2025. For further details, interested parties can contact Lisa Pendleton at lisa.pendleton@fda.hhs.gov or refer to the funding announcement at https://grants.nih.gov/grants/guide/rfa-files/RFA-FD-25-007.html.
    Reissue of RFA-FD-23-001- Clinical Studies of Orphan Products Addressing Unmet Needs of Rare Diseases (R01 Clinical Trials Required)
    Food and Drug Administration
    The U.S. Food and Drug Administration (FDA) has announced a Notice of Funding Opportunity (NOFO) titled "Reissue of RFA-FD-23-001 - Clinical Studies of Orphan Products Addressing Unmet Needs of Rare Diseases (R01 Clinical Trials Required)." This initiative aims to fund clinical trials that evaluate the efficacy and safety of orphan products for rare diseases, with the goal of addressing unmet medical needs and increasing the number of approved treatments in this area. The funding opportunity encourages innovative trial designs and collaboration among various stakeholders, emphasizing the importance of patient engagement throughout the research process. Eligible applicants include a wide range of organizations, with funding amounts reaching up to $900,000 per year, and applications are due by May 16, 2028. For further inquiries, interested parties can contact Kimberly Pendleton at Kimberly.Pendleton@fda.hhs.gov.
    Efficient and Innovative Natural History Studies Addressing Unmet Needs in Rare Diseases (R01 Clinical Trials Optional)
    Food and Drug Administration
    The Food and Drug Administration (FDA) is offering a funding opportunity titled "Efficient and Innovative Natural History Studies Addressing Unmet Needs in Rare Diseases (R01 Clinical Trials Optional)" aimed at supporting innovative studies that advance medical product development for rare diseases with unmet needs. The objective of this grant is to facilitate the collection of high-quality data that addresses critical knowledge gaps and removes barriers to progress in the field of rare diseases, ultimately impacting the development of medical products. This initiative is crucial for enhancing understanding and treatment options for rare diseases, which often lack sufficient research and resources. Interested applicants can apply for funding up to $400,000, with no cost-sharing requirements, and should direct inquiries to Kimberly Pendleton at Kimberly.Pendleton@fda.hhs.gov or call 240-402-7610. The opportunity is currently open and will be available for the fiscal year 2025.
    Reissue of RFA-FD-22-001 - Efficient and Innovative Natural History Studies Addressing Unmet Needs in Rare Diseases (R01 Clinical Trials Optional)
    Food and Drug Administration
    The Food and Drug Administration (FDA) is offering a funding opportunity titled "Reissue of RFA-FD-22-001 - Efficient and Innovative Natural History Studies Addressing Unmet Needs in Rare Diseases (R01 Clinical Trials Optional)." This initiative aims to support innovative natural history studies that generate high-quality data to advance medical product development for rare diseases with significant unmet needs. The funding is crucial for addressing knowledge gaps and facilitating the development of treatments in this area. Eligible applicants include a wide range of organizations such as higher education institutions, nonprofits, and government entities, with grant amounts reaching up to $600,000. The application deadline is February 8, 2028, and interested parties can contact Kimberly Pendleton at Kimberly.Pendleton@fda.hhs.gov for further information.
    NIOSH Support for Conferences and Scientific Meetings (R13 Clinical Trial Not Allowed)
    Centers for Disease Control and Prevention - ERA
    The Centers for Disease Control and Prevention (CDC) is offering a grant opportunity titled "NIOSH Support for Conferences and Scientific Meetings (R13 Clinical Trial Not Allowed)" aimed at supporting high-quality scientific meetings that advance research in occupational safety and health. Eligible applicants, including nonprofits without 501(c)(3) status and higher education institutions, are encouraged to submit proposals that align with NIOSH's strategic goals and the National Occupational Research Agenda (NORA), focusing on significant occupational health issues. This initiative underscores NIOSH's commitment to enhancing workplace safety through rigorous research and collaboration among experts, with a total funding amount of $500,000 available for up to five awards, each ranging from $10,000 to $20,000. Interested parties should submit their applications by December 15, 2025, and can contact Sharon Chou, Ph.D., at SChiou@cdc.gov for further information.
    Critical Path Public Private Partnerships Clinical Trials Optional
    Food and Drug Administration
    The Food and Drug Administration (FDA) is forecasting a grant opportunity titled "Critical Path Public Private Partnerships Clinical Trials Optional," aimed at supporting the continuation of existing consortia groups established by the Critical Path Institute. This initiative seeks applications to manage and maintain these groups, fostering innovative projects in research, education, and outreach to enhance drug product innovation and accelerate the development of therapeutics. The grant, which has an award ceiling and floor of $20 million, is expected to result in one award, with applications being accepted for the fiscal year 2024. Interested applicants can contact Terrin Brown at terrin.brown@fda.hhs.gov or (240) 402-7610 for further information.
    Retail Food Safety Regulatory Association Collaboration
    Food and Drug Administration
    The Food and Drug Administration (FDA) is offering a federal grant opportunity titled "Retail Food Safety Regulatory Association Collaboration" aimed at enhancing state, local, tribal, and territorial (SLTT) retail food safety programs. This cooperative agreement seeks to support non-profit national organizations affiliated with higher education institutions, focusing on reducing food-borne illness risk factors through research, intervention strategies, and other activities. The initiative is crucial for advancing a nationally integrated food safety system and alleviating the burden of foodborne illnesses. The estimated total program funding is $4 million, with approximately five awards expected, and interested applicants can contact Danielle Head at danielle.head@fda.hhs.gov or (301) 796-2984 for further information. The opportunity is open for the fiscal year 2026 and was last updated on August 4, 2025.